Last reviewed · How we verify
Part2: COVID-19 Vaccine, mRNA
Part2: COVID-19 Vaccine, mRNA is a Biologic drug developed by Jiangsu Rec-Biotechnology Co., Ltd.. It is currently in Phase 2 development. Also known as: Part2: COMIRNATY®.
At a glance
| Generic name | Part2: COVID-19 Vaccine, mRNA |
|---|---|
| Also known as | Part2: COMIRNATY® |
| Sponsor | Jiangsu Rec-Biotechnology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults (PHASE1, PHASE2)
- Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age (PHASE3)
- A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 (PHASE2, PHASE3)
- A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age (PHASE2, PHASE3)
- A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (PHASE3)
- Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Part2: COVID-19 Vaccine, mRNA CI brief — competitive landscape report
- Part2: COVID-19 Vaccine, mRNA updates RSS · CI watch RSS
- Jiangsu Rec-Biotechnology Co., Ltd. portfolio CI
Frequently asked questions about Part2: COVID-19 Vaccine, mRNA
What is Part2: COVID-19 Vaccine, mRNA?
Part2: COVID-19 Vaccine, mRNA is a Biologic drug developed by Jiangsu Rec-Biotechnology Co., Ltd..
Who makes Part2: COVID-19 Vaccine, mRNA?
Part2: COVID-19 Vaccine, mRNA is developed by Jiangsu Rec-Biotechnology Co., Ltd. (see full Jiangsu Rec-Biotechnology Co., Ltd. pipeline at /company/jiangsu-rec-biotechnology-co-ltd).
Is Part2: COVID-19 Vaccine, mRNA also known as anything else?
Part2: COVID-19 Vaccine, mRNA is also known as Part2: COMIRNATY®.
What development phase is Part2: COVID-19 Vaccine, mRNA in?
Part2: COVID-19 Vaccine, mRNA is in Phase 2.
Related
- Manufacturer: Jiangsu Rec-Biotechnology Co., Ltd. — full pipeline
- Also known as: Part2: COMIRNATY®
- Compare: Part2: COVID-19 Vaccine, mRNA vs similar drugs
- Pricing: Part2: COVID-19 Vaccine, mRNA cost, discount & access